Genentech

#Genentech #License agreement #Neuroscience #Parkinson's

Genentech licenses enzyme replacement therapy for Parkinson’s

Alector has granted Genentech worldwide rights to develop and commercialise its AL050 programme, a brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy (ERT).  As part of the deal, Alector will receive a $100 million upfront payment, with potential for up to $1.17 billion in additional milestone payments, as… Read More

#Business & Investment #News

FDA
#Autoimmune disease #FDA #Genentech

FDA approves obinutuzumab for rare autoimmune disease

The US Food and Drug Administration (FDA) has given the go-ahead to Genentech’s Gazyva (obinutuzumab) in adult and paediatric patients two years of age and older.  It is approved to reduce the risk of relapse in patients with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome… Read More

#News #Regulatory